Excessive activation of the complement system in atypical hemolytic uremic syndrome: Is it ready for prime time

Kidney International

Volumn 77, Issue 4, 2010, Pages 267-269

  Tsai, Han Mou ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR I; ECULIZUMAB;

CHROMOSOME 1Q; COMPLEMENT FACTOR 1 DEFICIENCY; COMPLEMENT SYSTEM; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; HEMOLYTIC UREMIC SYNDROME; HOMOZYGOSITY; HUMAN; INFECTION; KIDNEY FAILURE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; RISK FACTOR; SURVIVAL;

EID: 75749119748     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.467     Document Type: Note

References (13)

1. Tsai HM. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Kidney Int Suppl 2009; 75 (Suppl 112): S11-S14.
2. Skerka C, Jozsi M, Zipfel PF et al. Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost 2009; 101: 227-232.
3. Delvaeye M, Noris M, DeV A et al.Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 345-357.
4. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet [online 2004; 41: e84; doi:10.1136/jmg.2004.019083.
5. Abramson N, Alper CA, Lachmann PJ et al. Deficiency of C3 inactivator in man. J Immunol 1971; 107: 19-27.
6. Bienaime F, Dragon-Durey M-A, Regnier CH et al. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int 2010; 77: 339-349.
7. Dragon-Durey MA, Blanc C, Marliot F et al. T h e high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009; 46: 447-450.
8. Heinen S, Hartmann A,Lauer N et al. F a c t o r H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009; 114: 2439-2447.
9. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9: 729-740.
10. Rose KL, Paixao-Cavalcante D, Fish J et al. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest 2008; 118: 608-618.
11. Spencer KL, Hauser MA, Olson LM et al. Deletion of CFHR3 and CFHR1 genes in age-related macular degeneration. Hum Mol Genet 2008; 17: 971-977.
12. Nurnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542-544.
13. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 544-546.